SLC5A2 and heart failure: In addition, the Ertugliflozin for Functional Mitral Regurgitation Associated with Heart Failure: EFFORT Trial published by Kang et al. included 128 randomly assigned patients to receive either ertugliflozin or placebo and revealed satisfactory results supportive of SGLT2 inhibition regarding the management of HFpEF and HFmrEF and respective EF ranging from 35% to 50% associated with mitral regurgitation.